Clinical Trial

A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a prospective, single-arm, open-label and dose-escalation investigator initialed study to evaluate LUCAR-G79D in adult subjects with r/r SLE and r/r IIM.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-30.
Status change: Not Yet Recruiting → Recruiting 2026-01-29
Trial Details
NCT Number NCT07331272
Lead Sponsor Nanjing Legend Biotech Co.
Conditions Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathies(IIM)
Enrollment 38 participants
Start Date 2026-01-29
Primary Completion 2028-01-31 (estimated)
Study Completion 2030-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-02